177 related articles for article (PubMed ID: 198304)
41. Reduction of animal usage in the control of foot-and-mouth disease vaccines.
Strobbe R
Dev Biol Stand; 1986; 64():163-7. PubMed ID: 3025037
[TBL] [Abstract][Full Text] [Related]
42. [Attempts to adapt BNK cells to cultivation in suspension and study of the antigenic properties of foot-and-mouth diseases viruses obtained from them].
Mitev G; Tekerlekov P; Nikolova E
Vet Med Nauki; 1976; 13(7):91-5. PubMed ID: 189487
[TBL] [Abstract][Full Text] [Related]
43. Relationship of the antigenic structure of foot-and-mouth disease virus to the process of infection.
Rowlands DJ; Sangar DV; Brown F
J Gen Virol; 1971 Oct; 13(1):85-93. PubMed ID: 4331815
[No Abstract] [Full Text] [Related]
44. [Allergic reactions in cattle vaccinated against foot-and-mouth disease with vaccines prepared from viruses cultivated in BHK cells in roller bottles].
Pappous C; Verbelis P
Dev Biol Stand; 1976; 35():97-101. PubMed ID: 198319
[TBL] [Abstract][Full Text] [Related]
45. Detection of foot-and-mouth disease antigen in bovine epithelial samples: comparison of sites of sample collection by an enzyme linked immunosorbent assay (ELISA) and complement fixation test.
Oliver RE; Donaldson AI; Gibson CF; Roeder PL; Le Blanc Smith PM; Hamblin C
Res Vet Sci; 1988 May; 44(3):315-9. PubMed ID: 2841733
[TBL] [Abstract][Full Text] [Related]
46. [Comparison of the immunogenic potencies of purified inactivated foot-and-mouth disease virus particles with variable amounts of VP1 protein (author's transl)].
Bernard S; Grosclaude J; Adamowicz P; Guerche J
Ann Rech Vet; 1977; 8(1):79-94. PubMed ID: 195512
[No Abstract] [Full Text] [Related]
47. [Demonstration of antibody-synthesizing cells in mice and swine by means of local hemolysis in gel following immunization with foot-and-mouth disease virus and vaccine].
Wittmann G; Reda I
Zentralbl Bakteriol Orig A; 1974; 227(1-4):420-5. PubMed ID: 4154623
[No Abstract] [Full Text] [Related]
48. Inactivation of foot-and-mouth disease virus with ethylenimine.
Cunliffe HR
Appl Microbiol; 1973 Nov; 26(5):747-50. PubMed ID: 4357652
[TBL] [Abstract][Full Text] [Related]
49. A micro-enzyme-lavelled immunosorbent assay (MICORELISA) for the detection of foot-and-mouth disease virus antigen and antibody.
Rai A; Lahiri DK
Acta Virol; 1981 Jan; 25(1):49-52. PubMed ID: 6112866
[TBL] [Abstract][Full Text] [Related]
50. [Verification of a method of standardization of the antigens of anti-aphthous vaccine based on complement fixation capacity].
Strobbe R; Debecq J; Leunen J
Bull Off Int Epizoot; 1969; 71(3-4):397-404. PubMed ID: 4323528
[No Abstract] [Full Text] [Related]
51. [Antigenic structure of the foot-and-mouth disease virus (a review of the foreign literature)].
Sobko AI
Veterinariia; 1973 Sep; 9():103-4. PubMed ID: 4361327
[No Abstract] [Full Text] [Related]
52. [Antigenic structure of the foot-and-mouth-disease virus. I. Synthesis of protective peptides from the major immunogenic region of VP1 protein of foot-and-mouth virus type O1K].
Surovoĭ AIu; Vol'pina OM; Snetkova EV; Volkova TD; Ivanov VT
Bioorg Khim; 1988 Oct; 14(10):1352-62. PubMed ID: 2852937
[TBL] [Abstract][Full Text] [Related]
53. [Antigenic properties of foot-and-mouth disease virus strain Ai].
Darda PN; Salazhov EL; Antoniuk VP; Likhachev NV
Veterinariia; 1966 Jan; 43(1):20-2. PubMed ID: 4293892
[No Abstract] [Full Text] [Related]
54. Indirect complement fixation test with foot-and-mouth disease virus antigen concentrated by polyethylene glycol precipitation.
Sakaki K; Suphavilai P; Kongthon S
Natl Inst Anim Health Q (Tokyo); 1978; 18(1):8-17. PubMed ID: 206842
[TBL] [Abstract][Full Text] [Related]
55. [Changes in antigen properties of foot-and-mouth disease virus during several passages].
Salajov EL; Avilov VS; Revenkov AG
Bull Off Int Epizoot; 1972; 77(5):935-40. PubMed ID: 4350009
[No Abstract] [Full Text] [Related]
56. [Effects of gamma radiation on the infectivity, antigenicity and immunogenicity of the foot-and-mouth disease virus].
Frescura T; Massa D; Cardaras P
Boll Ist Sieroter Milan; 1972; 51(2):109-17. PubMed ID: 4345590
[No Abstract] [Full Text] [Related]
57. [Report on the characteristics of foot-and-mouth disease virus capable of being used as live vaccines].
Asso J; Paraf A; Aynaud JM; Lucas A; Dhennin L; Gayot G
Bull Off Int Epizoot; 1966; 65(11):1929-36. PubMed ID: 4296532
[No Abstract] [Full Text] [Related]
58. Haemagglutination by type SAT 2 foot-and-mouth disease viruses.
Booth JC; Pay TW
J Gen Virol; 1973 Jun; 19(3):397-404. PubMed ID: 4353214
[No Abstract] [Full Text] [Related]
59. Three variants of foot-and-mouth disease virus type O: agar gel diffusion reactions.
McVicar JW; Sutmoller P
Am J Vet Res; 1972 Aug; 33(8):1635-9. PubMed ID: 4340053
[No Abstract] [Full Text] [Related]
60. The suitability of a rolled BHK21 monolayer system for the production of vaccines against the SAT types of foot-and-mouth disease virus. I. Adaptation of virus isolates to the system, immunogen yields achieved and assessment of subtype cross reactivity.
Esterhuysen JJ; Thomson GR; Ashford WA; Lentz DW; Gainaru MD; Sayer AJ; Meredith CD; Janse van Rensburg D; Pini A
Onderstepoort J Vet Res; 1988 Jun; 55(2):77-84. PubMed ID: 2839810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
